Skip to content

Tango Therapeutics TNGX Book value per share

Book value per share at other companies

Amgen logo
AmgenAMGN
$16.89+47.2%
Gilead Sciences logo
Gilead SciencesGILD
$18.75+23.2%
Exelixis logo
ExelixisEXEL
$7.24-2.1%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$3.75+93.9%
CG Oncology logo
CG OncologyCGON
$12.92+39.6%
Lantheus Holdings logo
Lantheus HoldingsLNTH
$18.43+13.1%

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%
Enterprise value$4.43B+2,204%
P/S79.9×+74.4×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Calculated from Tango Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's book value per share?
Tango Therapeutics (TNGX) reported book value per share of $2.73 in Q1 2026.
How has Tango Therapeutics's book value per share changed year-over-year?
Tango Therapeutics's book value per share increased by 80.4% year-over-year, from $1.51 to $2.73.
What is the long-term trend for Tango Therapeutics's book value per share?
Over 5 years (2020 to 2025), Tango Therapeutics's book value per share has grown at a 5.2% compound annual growth rate (CAGR), from $2.31 to $2.98.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.